Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report)'s stock price traded down 7.6% during trading on Tuesday . The stock traded as low as $36.70 and last traded at $36.26. 792,265 shares were traded during trading, an increase of 35% from the average session volume of 588,927 shares. The stock had previously closed at $39.24.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the stock. Wedbush restated an "outperform" rating and set a $90.00 price objective on shares of Apogee Therapeutics in a report on Monday. Guggenheim restated a "buy" rating and set a $116.00 price objective on shares of Apogee Therapeutics in a report on Wednesday, July 2nd. Citigroup restated a "buy" rating on shares of Apogee Therapeutics in a report on Monday. Finally, BTIG Research boosted their price objective on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a report on Monday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $99.00.
Get Our Latest Stock Report on Apogee Therapeutics
Apogee Therapeutics Price Performance
The stock's 50 day simple moving average is $40.31 and its two-hundred day simple moving average is $38.91. The stock has a market cap of $1.73 billion, a P/E ratio of -10.47 and a beta of 1.47.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, beating analysts' consensus estimates of ($1.19) by $0.24. As a group, analysts forecast that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.
Insider Activity at Apogee Therapeutics
In other news, insider Carl Dambkowski sold 10,090 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $45.09, for a total value of $454,958.10. Following the sale, the insider owned 238,998 shares of the company's stock, valued at $10,776,419.82. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 15,540 shares of company stock valued at $653,093 over the last 90 days. Insiders own 42.77% of the company's stock.
Institutional Trading of Apogee Therapeutics
A number of institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Apogee Therapeutics by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company's stock worth $921,000 after purchasing an additional 694 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Apogee Therapeutics during the fourth quarter worth $43,000. Arizona State Retirement System raised its position in Apogee Therapeutics by 17.3% during the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company's stock worth $295,000 after acquiring an additional 960 shares in the last quarter. Granahan Investment Management LLC raised its position in Apogee Therapeutics by 1.2% during the fourth quarter. Granahan Investment Management LLC now owns 92,854 shares of the company's stock worth $4,206,000 after acquiring an additional 1,097 shares in the last quarter. Finally, Brooklyn Investment Group bought a new stake in Apogee Therapeutics during the first quarter worth $42,000. Institutional investors own 79.04% of the company's stock.
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Read More
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
